On June 3, 2025, the pharmaceutical company Sanofi signed Memoranda of Understanding with the Private Higher Education Institution Dobrobut Academy and the Dobrobut Medical Network. The partnership aims to significantly improve patient access in Ukraine to innovative methods for the diagnosis and treatment of orphan diseases, cardiovascular diseases, diabetes mellitus, and to improve the level of immunoprophylaxis.
In particular, the partners are joining forces within the Orphan Diseases Academy project, which aims to detect rare hereditary diseases at an early stage and provide comprehensive support to patients, including through free access to highly specialized laboratory diagnostics abroad.
Another important area of cooperation is the development of preventive and educational programs on diabetes and cardiovascular diseases, as well as the organization of training courses and workshops for medical professionals using modern methods and experts. This contributes to improving the professional level of doctors and introducing advanced technologies into medical practice.
Particular attention is paid to the introduction of digital solutions for patient monitoring and the active promotion of vaccination as a key tool for protecting public health, which contributes to strengthening immunoprophylaxis and increasing vaccination literacy.
“At a time when Ukraine’s healthcare system is facing unprecedented challenges, reliable partnerships are crucial. We are delighted that new partners are joining Sanofi’s educational initiatives – the Dobrobut medical network and the Dobrobut Academy, leading medical institutions that share our values of quality, accessibility, and trust. Working together on early diagnosis, training healthcare professionals, introducing innovative technologies, and strengthening immunoprophylaxis will expand the possibilities for helping patients and reinforce our common goal of providing Ukrainians with adequate support regardless of their circumstances,” said Olena Bushmina, Head of the Pharmaceutical Division at Sanofi in Ukraine.
“I am very pleased that two leading healthcare companies, Dobrobut and Sanofi, have signed a memorandum. After all, we are talking about concrete actions for the health of Ukrainians. Our cooperation will provide hundreds of patients with orphan, endocrinological, and cardiovascular diseases with access to the best modern diagnostics and necessary knowledge. I have no doubt that our joint efforts will bear fruit: a better quality of life and hope for those who need support, said Serhiy Orel, CEO of the Dobrobut medical network.
“At a time when every initiative can save lives, joining forces is not just important — it is vital. For the Dobrobut Academy, this partnership is not just about education. It is about hope for patients, new horizons for doctors, and the belief that even in the most difficult times, we can build a future together. We are proud to be part of this great cause,” said Nana Voitenko, rector of the Dobrobut Academy, professor, and doctor of biological sciences.
The cooperation agreement was signed at the Dobrobut Academy, a private higher education institution, with the participation of Olena Bushmina, Head of the Pharmaceutical Division at Sanofi Ukraine, Serhii Orla, CEO of the Dobrobut Medical Network, and Nana Voitenko, Rector of the Dobrobut Academy.
The 2023/2024 season quadrivalent influenza vaccine manufactured by Sanofi has been delivered to pharmacies and private clinics.
According to Sanofi in its press release, the influenza vaccine supplied to Ukraine is suitable for protecting adults, including pregnant women, as well as adolescents and children aged 6 months and older. In addition, it provides passive protection for infants up to 6 months of age when administered to pregnant women.
According to Anna Pastushyna, Head of Sanofi Vaccines in Ukraine, the 2022/2023 season saw an increased demand for vaccines due to the high prevalence of influenza after the easing of COVID-19 restrictions.
“The company plans to fulfill its obligations to supply influenza vaccine in the countries where it operates,” she emphasized.
For his part, Fedir Lapiy, head of the National Technical Group of Experts on Immunization, noted that “influenza can worsen a number of pre-existing chronic respiratory disorders, including asthma and chronic obstructive pulmonary disease.”
“Adults over the age of 40 are eight times more likely to have a first stroke after being infected with influenza, while in children under 14, influenza increases the risk of pneumonia eightfold. Almost every third elderly person hospitalized with influenza develops pneumonia. And for people with diabetes, the risk of hospitalization during the flu epidemic is six times higher,” he said.
As reported, according to the Center for Public Health (CDC), 3.9 million cases of influenza and more than 140 thousand hospitalizations caused by the influenza virus were reported during the previous flu season of 2022/2023 (from September 2022 to April 2023).
“Sanofi is an innovative global healthcare company operating in 100 countries.
As reported, 151,100 thousand doses of the French influenza vaccine and 114.6 thousand doses of the Korean vaccine will be supplied in the 2023/24 epidemic season.
The commercial cassation court of the Supreme Court of Ukraine has supported the pharmaceutical distributor of Ukrainian-Estonian joint venture Optima-Pharm Ltd. in the lawsuit against the Antimonopoly Committee of Ukraine regarding Sanofi pharmaceutical company. The authorized government official at the Antimonopoly Committee of Ukraine, Svitlana Panaiotidi, gave this information. “Today we lost the Supreme Court case. It was the lawsuit of the Optima-Pharm distributor in the Sanofi case,” she wrote on her Facebook page on Tuesday.
As reported, in September 2018, Kyiv’s business court of appeals upheld the ruling of the court of lower instance, which satisfied a claim of the distributor of medicines Optima-Pharm LLC against the Antimonopoly Committee of Ukraine regarding the annulment of a fine of UAH 40.759 million imposed for anticompetitive actions committed jointly with Sanofi-Aventis Ukraine LLC. According to the ruling issued on September 4, 2018, the panel of judges of the appeal court agreed with the conclusion of the court of lower instance that the committee when making decision No. 628-r did not clarify the circumstances in full.
In October 2018, Kyiv’s business court has overturned the decision of the Antimonopoly Committee of Ukraine to collect the UAH 70 million fine from Sanofi pharmaceutical company.
In 2017, the Antimonopoly Committee of Ukraine fined Sanofi-Aventis Ukraine and its distributors BaDM LLC and Optima-Pharm LLC in the total amount of UAH 139.094 million for supplies of medicines in 2020-2011.
